Skip to main content
Premium Trial:

Request an Annual Quote

In Vitro Technologies Distributing Seahorse Bio Products in Australia, New Zealand

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Seahorse Bioscience announced today that In Vitro Technologies is the new distributor of its Seahorse XF Analyzers and consumables in Australia and New Zealand.

Financial and other terms were not disclosed.

Seahorse Extracellular and Flux Analyzers provide the first and only kinetic method of measuring mitochondrial respiration and glycolysis, the two major energy-producing pathways, in living cells in a microplate, the North Billerica, Mass., firm said. The analyzers allow scientists to assess the impact of drugs, genetic modifications, and environment by monitoring oxygen consumption and the production of metabolic byproducts in cells.

"Our goal was to partner with a distributor who provides quality sales, service, and support to customers in the cell-based assay market," Steve Chomicz, vice president of sales and marketing for Seahorse, said in a statement. "The partnership with In Vitro will allow us to accelerate our sales as they have existing relationships with our ideal customer base."

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.